TECHULON, INC. — Department of Defense SBIR Phase I: Drug resistant pathogens represent a growing and significant risk. Post-treatment hospital

Description

Drug resistant pathogens represent a growing and significant risk. Post-treatment hospital infections account for over 90,000 deaths per year and an additional $30b in cost to the healthcare infrastructure. Techulon intends to commercialize a flexible system to significantly impact the $40b antibiotic marketplace. The company proposes the development of a scalable and adaptable system for neutralizing drug-resistant bacteria through a novel nanoparticle platform. The company will leverage the use of informatics for pathogen identification and a polymer-based platform for nanoparticle delivery of targeted peptide-RNA sequences specific for each threat. Techulon has assembled a qualified and experienced team to prove feasibility of pathogen identification, platform development, and in vitro feasibility. The company will develop a robust system capability from foundational technologies that exist today. Techulon has pioneered a new family of polymers that can overcome the major obstacles of in vivo RNA delivery. The company proposes a means to treat extracellular, intracellular and viral infections that can be quickly adapted to novel and engineered threats. The research will focus on advancing the technology readiness level by refining and demonstrating feasibility, leading to a Phase II in vivo demonstration.